Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation DayGlobeNewsWire • 07/09/24
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and EfficacyGlobeNewsWire • 07/08/24
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingGlobeNewsWire • 06/14/24
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingGlobeNewsWire • 06/01/24
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingGlobeNewsWire • 05/23/24
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual MeetingGlobeNewsWire • 05/22/24
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingGlobeNewsWire • 05/14/24
Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should KnowZacks Investment Research • 05/03/24
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/02/24
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/25/24
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingGlobeNewsWire • 04/08/24
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have FaithSeeking Alpha • 03/21/24
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/08/24
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 02/22/24
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/15/24